In another study, TP53 co-mutation was discovered as a predictor for TKI efficacy and survival in EGFR+ NSCLC irrespective of other currently available parameters and it might be an important factor for risk stratification of newly diagnosed metastatic EGFR+ NSCLC (35). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.